RAF1 and melanoma: Switching from B-Raf to either Raf-1 or A-Raf was observed after incubation of melanoma cells containing the BRAF V600E mutation in the presence of the B-Raf inhibitor dabrafenib for prolonged periods of time in the recovered inhibitor-resistant cells.